List of works - Kalijn Bol

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

scientific article published on 29 July 2016

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

scientific article published on 31 May 2016

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

scientific article published on 24 January 2020

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

scientific article published on 01 October 2018

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

scientific article published on April 2016

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

scientific article published on 7 May 2017

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy

scientific article published on 04 March 2019

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

scientific article published on 5 June 2015

Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know

scientific article published on 23 July 2020

Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy

article

Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination

scientific article published on 01 January 2020

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.

scientific article published on 25 May 2016

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.

scientific article published on 14 May 2013

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

scientific article published on April 2015

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

scientific article published on 17 June 2016

Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients

scientific article published on 17 July 2014

Naturally circulating dendritic cells to vaccinate cancer patients.

scientific article published on March 2013

Prognostic significance and mechanism of Treg infiltration in human brain tumors.

scientific article

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

scientific article

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma

scientific article published on 12 November 2020

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

scientific article published on 03 October 2019

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

scientific article published on 21 November 2008

Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma

scientific article published on 24 September 2012

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

scientific article published on 11 April 2016

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination

scientific article published on 18 October 2012

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

scientific article published on 18 April 2019

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients